Organic Active Ingredients TRIZ Cases

Unsubstituted benzyl ester masking groups resist esterase metabolism in blood, reducing systemic toxicity while maintaining anti-virus activity.

A cell-specific expression platform uses microRNA override to control modified messenger RNA translation in target tissues.

Segmented molecular structures resolve the trade-off between therapeutic efficacy and option availability, treating fibrosis and cancer.

A benzothiazole derivative with specific alkyl and cycloalkyl substituents inhibits B-Raf kinase activity.

Novel Lactobacillus plantarum strains inhibit urogenital pathogens and form protective biofilms.

Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one derivatives resolve chemical stability and selectivity trade-offs in MDM2-p53 inhibition.

A low pH topical composition enhances hyaluronic acid penetration through the skin barrier.

Segmenting tissue nitric oxide from mobile NO-haem species resolves detection ambiguity in NOS signaling networks.

Formula I compounds lower LDL-C by 40% and raise HDL-C by 138% while minimizing off-target activity.

Bicyclic heteroaryl phosphonate compounds inhibit ENPP1 to prevent cGAMP hydrolysis and enhance immune responses against cancer.

Cellulose derivative coatings replace polyvinyl alcohol in immediate release Ribociclib tablets, resolving dissolution limitations while maintaining stability.

Binding isoflavones to whey proteins reduces plasma lipids and improves insulin sensitivity while avoiding estrogenic side effects.

Polymeric coating with surfactants masks bitter taste and enables 60-second LC-MS/MS trace detection on tablet surfaces.

Momordicin I derivatives inhibit cancer cell proliferation through targeted molecular mechanisms.

Formula I derivatives resolve the trade-off between enzymatic activity and bioavailability by enhancing p21 induction capacity.

In situ solid implant uses phase transitions to eliminate lag phase and oral supplementation needs.

Targeting phosphatidylinositol-4-kinase IIIβ reduces toxic side effects while maintaining effective immunosuppression for transplant rejection.

KDM5D biomarker testing stratifies patients to optimize survival while reducing side effects from unnecessary combination therapy.

IL-2 conjugates expand CD8+ and NK cells while avoiding Treg expansion that causes vascular leak syndrome.

Selective Formula I compounds inhibit the ROMK channel to lower blood pressure without causing hypokalemia.

Polycyclic carbamoylpyridone compounds inhibit HIV replication while minimizing PXR activation to prevent drug-drug interactions.

Crosslinked polymer matrices provide sustained drug delivery, improving bioavailability and reducing side effects from poor penetration.

Acid protonation dissolves insoluble chitosan while controlled deacetylation preserves bioactivity against lysozyme depolymerization.

Targeting hypoxia-inducible factors reduces GvHD while preserving anti-tumor immunity.

USP11 modulation restores homologous recombination in G1 cells, sensitizing BRCA-deficient tumors to PARP inhibitors and delaying treatment resistance.

A topical composition solubilizes usnic acid using ethoxylated hydrogenated castor oil derivatives and polypropylene glycol buteth.

Spiro cyclopropyl indolinone compounds act as potent kinase inhibitors targeting PLK4 and Aurora Kinases.

Thienopyridone derivatives directly activate AMPK isoforms to reduce renal cyst volume, avoiding lactic acidosis and high oral doses associated with metformin.

A morphine infusion dosage form uses an inert gas or vacuum layer between the container and outer covering to maintain chemical stability.

Administering fluconazole alongside an immunogenic Als3 polypeptide combats recurrent vulvovaginal candidiasis by establishing long-term immune protection.

Substituted 3-phenyl-1H-indole derivatives inhibit tryptophan 2,3-dioxygenase while preventing cross-reactivity with IDO1 and CYP enzymes to eliminate toxicity.

Acyclic oxazepine compounds inhibit mutant KRas proteins, addressing inadequate therapies for KRas-mediated cancers.

Genotyping PARP1 polymorphisms predicts chemotherapy resistance, enabling personalized treatment selection.

Novel MCT4 inhibitors target monocarboxylate transporter 4 activity to block lactate secretion in cancer cells.

Administering CXCR4 antagonist peptides before chemotherapy disrupts bone marrow adhesion, reducing non-target toxicity while improving treatment efficacy.

Synergistic adaptogen formulations normalize hypothalamic-pituitary-adrenal axis activity, mitigating cannabis-induced fatigue and anxiety.

Isolating vandaterosides from Papilionanthe teres to stimulate the mitochondrial respiratory chain and promote cellular differentiation.

1H-indazole-3-carboxamide compounds selectively inhibit glycogen synthase kinase 3 beta to treat insulin resistance and neurodegenerative diseases.

Continuous 4-aminopyridine release over weeks reduces scarring and lesion size while providing sustained trophic support.

Substituted benzamides target trace amine associated receptor 1 for treating psychiatric disorders.

Poziotinib overcomes steric hindrance in HER2 exon 19 mutations via structural flexibility.

Puerariae radix extract reduces beta-amyloid accumulation and tau hyperphosphorylation, addressing side effects of synthetic Alzheimer's drugs.